HC Wainwright Has Bearish Forecast for Brainsway Q4 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for shares of Brainsway in a research report issued to clients and investors on Friday, October 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.06 per share for the quarter, down from their previous forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Brainsway’s Q2 2026 earnings at $0.06 EPS.

Other research analysts have also issued research reports about the company. Northland Securities raised their price objective on Brainsway from $15.00 to $19.00 and gave the company an “outperform” rating in a report on Thursday, August 14th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Brainsway in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Brainsway has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Brainsway Price Performance

Shares of NASDAQ:BWAY opened at $16.85 on Monday. Brainsway has a 1 year low of $7.84 and a 1 year high of $17.49. The firm has a market capitalization of $320.15 million, a PE ratio of 64.81 and a beta of 1.22. The business’s 50 day moving average price is $15.73 and its 200-day moving average price is $12.81.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.07 by $0.03. The company had revenue of $12.63 million during the quarter, compared to analyst estimates of $12.34 million. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. Brainsway has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Brainsway

A number of institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in Brainsway in the 2nd quarter valued at about $85,000. Trexquant Investment LP acquired a new position in Brainsway in the first quarter valued at approximately $129,000. NewEdge Advisors LLC grew its position in Brainsway by 61.5% in the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after acquiring an additional 7,549 shares during the period. Eagle Global Advisors LLC acquired a new stake in Brainsway during the first quarter worth $590,000. Finally, Huntleigh Advisors Inc. increased its stake in Brainsway by 5.7% during the second quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock worth $1,018,000 after acquiring an additional 4,143 shares during the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.